Law360, New York (March 24, 2008, 12:00 AM ET) -- Forest Laboratories Inc. has launched yet another patent infringement lawsuit in an effort to prevent a generic version of the company's Alzheimer’s drug, Namenda, from reaching the market.
Forest and Merz Pharma GmbH & Co. KgaA filed suit Thursday against Synthon Pharmaceuticals Inc., Synthon's parent company and two subsidiaries in the U.S. District Court for the Eastern District of North Carolina, alleging that the generics manufacturer filed an abbreviated new drug application to market and sell generic tablets of Namenda before the patent expires.
The North...
Forest Sues Sython To Protect Namenda Patent
To view the full article, take a free trial now.
